BMS, Pfizer File Multiple Eliquis Patent Suits

Apr 12, 2017

Delaware Law Weekly

Bristol-Myers Squibb and Pfizer filed multiple patent infringement suits in Delaware to protect patents for the profitable blood thinner, Eliquis.

The companies, which jointly develop the drug, filed suits against 13 generic drugmakers this week, plus three the week prior, who had planned to produce generic versions of Eliquis. Companies named include Mylan, Dr. Reddy’s Labs and Accord Healthcare.

In the Delaware litigation, BMS and Pfizer are seeking declarations that two patents for Eliquis are valid and enforceable, and allege the planned generics would infringe on one owned by Bristol-Myers Squibb and another owned by both companies.

Read the Delaware Law Weekly coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments